Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized antiretroviral therapy versus standard triple therapy in primary HIV-1 infection
2009-014742-28Phase 3Active
- Sponsor
- ANRS
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of raltegravir, maraviroc, darunavir, ritonavir, emtricitabine and 1 more in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ANRS. Primary endpoint: Immunovirological criteria. Started Oct 2009; status: active.
02
Drugs
raltegravirmaravirocdarunavirritonaviremtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-014742-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014742-28.